Benjamin Looker
2022
In 2022, Benjamin Looker earned a total compensation of $1.3M as General Counsel at Esperion Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $165,000 |
|---|---|
| Option Awards | $485,002 |
| Salary | $375,000 |
| Stock Awards | $258,420 |
| Other | $10,350 |
| Total | $1,293,772 |
Looker received $485K in option awards, accounting for 37% of the total pay in 2022.
Looker also received $165K in non-equity incentive plan, $375K in salary, $258.4K in stock awards and $10.4K in other compensation.
Rankings
In 2022, Benjamin Looker's compensation ranked 2,530th out of 5,736 executives tracked by ExecPay. In other words, Looker earned more than 55.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,530 out of 5,736 | 56th |
Division Manufacturing | 1,397 out of 3,125 | 55th |
Major group Chemicals And Allied Products | 634 out of 1,416 | 55th |
Industry group Drugs | 588 out of 1,317 | 55th |
Industry Pharmaceutical Preparations | 421 out of 963 | 56th |
Source: SEC filing on April 13, 2023.
Looker's colleagues
We found two more compensation records of executives who worked with Benjamin Looker at Esperion Therapeutics in 2022.